ECSP17026687A - Compuesto heterocíclico - Google Patents

Compuesto heterocíclico

Info

Publication number
ECSP17026687A
ECSP17026687A ECIEPI201726687A ECPI201726687A ECSP17026687A EC SP17026687 A ECSP17026687 A EC SP17026687A EC IEPI201726687 A ECIEPI201726687 A EC IEPI201726687A EC PI201726687 A ECPI201726687 A EC PI201726687A EC SP17026687 A ECSP17026687 A EC SP17026687A
Authority
EC
Ecuador
Prior art keywords
rbp4
heterocyclic compound
retinol
medicament
disease
Prior art date
Application number
ECIEPI201726687A
Other languages
English (en)
Inventor
Yuping Zhu
Christina Madsen-Duggan
Llc Wyeth
Ahmet Kekec
Danqing Feng
Original Assignee
Eh Europe Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eh Europe Gmbh filed Critical Eh Europe Gmbh
Publication of ECSP17026687A publication Critical patent/ECSP17026687A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/38—One oxygen atom attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Se proporciona un compuesto heterocíclico que tiene una acción superior de reducción de RBP4 y de utilidad como un medicamento para la prevención o el tratamiento de una enfermedad o un síntoma mediados por un incremento en RBP4 o retinol proporcionado por RBP4. Un compuesto representado por la fórmula (I) (Descrita en la imagen que se remite en archivo adjunto) en donde cada símbolo es como se define en la descripción o una sal del mismo tiene una acción superior de reducción de RBP4 y es de utilidad como un medicamento para la prevención o el tratamiento de una enfermedad o síntoma mediados por un incremento en RBP4 o retinol proporcionado por RBP4.
ECIEPI201726687A 2014-10-24 2017-04-28 Compuesto heterocíclico ECSP17026687A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014217770 2014-10-24

Publications (1)

Publication Number Publication Date
ECSP17026687A true ECSP17026687A (es) 2017-09-29

Family

ID=55760964

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201726687A ECSP17026687A (es) 2014-10-24 2017-04-28 Compuesto heterocíclico

Country Status (38)

Country Link
US (4) US10214498B2 (es)
EP (2) EP3210973B1 (es)
JP (2) JP6588027B2 (es)
KR (1) KR102490156B1 (es)
CN (2) CN107108506B (es)
AR (1) AR104342A1 (es)
AU (2) AU2015336480B2 (es)
BR (1) BR112017007138A2 (es)
CA (1) CA2965465C (es)
CL (1) CL2017000944A1 (es)
CO (1) CO2017003699A2 (es)
CR (1) CR20170160A (es)
CY (1) CY1123842T1 (es)
DK (1) DK3210973T3 (es)
DO (1) DOP2017000098A (es)
EA (1) EA033446B1 (es)
EC (1) ECSP17026687A (es)
ES (1) ES2848999T3 (es)
HR (1) HRP20210320T1 (es)
HU (1) HUE053443T2 (es)
IL (2) IL285105B2 (es)
LT (1) LT3210973T (es)
MA (2) MA53568A (es)
MX (2) MX2017004629A (es)
MY (1) MY183209A (es)
PE (1) PE20170669A1 (es)
PH (1) PH12017500747A1 (es)
PL (1) PL3210973T3 (es)
PT (1) PT3210973T (es)
RS (1) RS61504B1 (es)
SG (1) SG11201702312UA (es)
SI (1) SI3210973T1 (es)
SM (1) SMT202100082T1 (es)
TN (1) TN2017000097A1 (es)
TW (2) TWI749661B (es)
UA (1) UA121871C2 (es)
WO (1) WO2016063933A1 (es)
ZA (1) ZA201703344B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61504B1 (sr) * 2014-10-24 2021-03-31 Takeda Pharmaceuticals Co Jedinjenja heteroarila za lečenje oftalmičkih bolesti
KR102717545B1 (ko) 2017-03-20 2024-10-16 더 브로드 인스티튜트, 인코퍼레이티드 기생충성 질환의 치료를 위한 화합물 및 방법
US11389444B2 (en) * 2017-06-15 2022-07-19 Belite Bio, Inc Methods of treating metabolic diseases with fused bicyclic pyrazoles
EP3638239A4 (en) 2017-06-15 2021-03-10 Belite Bio, Inc METHOD OF TREATMENT OF RBP4-RELATED DISEASES WITH TRIAZOLOPYRIDINES
US12440486B2 (en) 2018-08-01 2025-10-14 The Trustees Of Columbia University In The City Of New York RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout
CN111690698A (zh) * 2020-05-19 2020-09-22 浙江工业大学 两步串联流动合成3-（苯并[d][1,3]二氧-5-氨基）丙羟肟酸的方法
CN111690695A (zh) * 2020-05-19 2020-09-22 浙江工业大学 3-苯氨基丙羟肟酸的酶促微流控在线合成方法
AU2022276517A1 (en) * 2021-05-21 2023-12-07 Belite Bio, Llc Biomarkers for age-related macular degeneration
WO2022256301A1 (en) * 2021-06-01 2022-12-08 Stargazer Pharmaceuticals, Inc. Methods and compounds for treating subjects with stargardt disease
CN116286900B (zh) * 2022-10-28 2024-04-26 昆明理工大学 一种乙酸渗透酶A基因RkAcpa及其应用
CN116019791B (zh) * 2022-12-28 2025-12-16 浙江工业大学台州研究院 二苯醚类化合物在制备β-葡萄糖醛酸苷酶抑制剂中应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625970A (en) 1968-04-17 1971-12-07 Cutter Lab 1-(disubstituted phenyl or benzyl)-1h-indazol-3-yloxyacetic acid
US5239080A (en) 1989-02-08 1993-08-24 Takeda Chemical Industries, Ltd. Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents
EP0440183A1 (en) * 1990-02-01 1991-08-07 Takeda Chemical Industries, Ltd. Oxazole compounds, their production and use
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
WO2001025228A1 (en) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Amine derivatives
PL356487A1 (en) 1999-11-10 2004-06-28 Takeda Chemical Industries, Ltd. 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
GB0020351D0 (en) 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases
DE10149568A1 (de) 2001-10-08 2003-04-24 Consequence Gmbh Verfahren zur Sequenzanalyse von Polypeptiden
WO2003042204A1 (en) 2001-10-19 2003-05-22 Takeda Chemical Industries, Ltd. Amine derivative
US20040214788A1 (en) 2003-03-11 2004-10-28 Raj Madhwa H.G. Treatment of prostate cancer
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
CA2532026C (en) 2003-08-20 2012-04-17 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
JP4869942B2 (ja) 2003-12-11 2012-02-08 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド インスリン感受性／抵抗性、糖尿病および肥満におけるｒｂｐ４
WO2005120583A2 (en) 2004-06-14 2005-12-22 Wisconsin Alumni Research Foundation Method for preventing or treating cardiac hypertrophy
PL1768657T3 (pl) 2004-06-23 2009-01-30 Revision Therapeutics Inc Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych
US20080033053A1 (en) 2004-07-22 2008-02-07 Wolfgang Curt D Cross-Reference To Related Applications
US7947267B2 (en) 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
CN101500594A (zh) 2006-06-22 2009-08-05 西来昂诊疗公司 通过调节巨蛋白活性治疗眼病的方法和组合物
CA2691003A1 (en) 2007-06-26 2008-12-31 Lexicon Pharmaceuticals, Inc. Methods of treating serotonin-mediated diseases and disorders
EP2170335A1 (en) 2007-06-26 2010-04-07 Lexicon Pharmaceuticals, Inc. Compositions comprising tryptophan hydroxylase inhibitors
US7973079B2 (en) 2007-09-27 2011-07-05 Revision Therapeutics, Inc. Methods and compounds for treating retinol-related diseases
JP2010540541A (ja) * 2007-09-27 2010-12-24 リヴィジョン セラピューティクス，インク． レチノール関連疾患を治療するための方法及び化合物
EP2202223B1 (en) * 2007-10-18 2017-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound as blood rbp4 lowering agent
WO2009143390A2 (en) 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc. Methods for modulating expression of rbp4
CA2725680A1 (en) * 2008-05-30 2009-12-03 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR20120022927A (ko) * 2009-04-13 2012-03-12 아이알엠 엘엘씨 레티놀 결합 단백질 4 (ｒｂｐ4)에 대한 레티놀 결합을 조절하기 위한 조성물 및 방법
JP5706337B2 (ja) * 2009-04-16 2015-04-22 武田薬品工業株式会社 （とりわけ）糖尿病の予防または治療に有用なｎ−アシル−ｎ’−フェニルピペラジンの誘導体
EP2521541A2 (en) 2009-10-28 2012-11-14 ReVision Therapeutics, Inc. Prophylaxis of skin cancer with retinamides
AU2010327936B2 (en) 2009-12-11 2015-08-20 Nono Inc. Agents and methods for treating ischemic and other diseases
EP2560966B1 (en) 2010-03-30 2021-01-06 Verseon International Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
WO2012071369A2 (en) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
WO2012154967A1 (en) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
GB201205679D0 (en) 2012-03-30 2012-05-16 Dyson Technology Ltd A hand held appliance
WO2013166041A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular
US9580400B2 (en) 2013-02-26 2017-02-28 Northeastern University Cannabinergic nitrate esters and related analogs
US20160030422A1 (en) 2013-03-14 2016-02-04 Konstantin Petrukhin Rbp4 antagonists for the treatment of age-related macular degeneration and stargardt disease
WO2014153643A1 (en) 2013-03-26 2014-10-02 The University Of British Columbia Compositions and methods for use thereof in the treatment of aniridia
EP3114109A4 (en) 2014-03-07 2017-10-18 The Johns Hopkins University Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
RS61504B1 (sr) * 2014-10-24 2021-03-31 Takeda Pharmaceuticals Co Jedinjenja heteroarila za lečenje oftalmičkih bolesti
TN2017000158A1 (en) 2014-10-24 2018-10-19 Bristol Myers Squibb Co Carbazole derivatives
PT3461821T (pt) 2014-10-24 2020-08-05 Bristol Myers Squibb Co Compostos de indol carboxamida úteis como inibidores de quinase
US11040976B2 (en) 2015-04-24 2021-06-22 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use

Also Published As

Publication number Publication date
TN2017000097A1 (en) 2018-07-04
HUE053443T2 (hu) 2021-06-28
EP3210973A4 (en) 2018-04-25
ES2848999T3 (es) 2021-08-13
HRP20210320T1 (hr) 2021-04-30
JPWO2016063933A1 (ja) 2017-08-03
EP3848353A1 (en) 2021-07-14
IL251695B (en) 2021-08-31
US10544111B2 (en) 2020-01-28
CN115197160A (zh) 2022-10-18
US20200157062A1 (en) 2020-05-21
CA2965465C (en) 2023-08-01
PL3210973T3 (pl) 2021-06-28
JP6995094B2 (ja) 2022-02-21
MA53568A (fr) 2022-02-23
SG11201702312UA (en) 2017-05-30
US10975043B2 (en) 2021-04-13
AU2020204426B2 (en) 2022-02-03
IL285105B (en) 2022-11-01
IL285105B2 (en) 2023-03-01
WO2016063933A1 (ja) 2016-04-28
AU2020204426A1 (en) 2020-07-23
CL2017000944A1 (es) 2018-01-12
IL251695A0 (en) 2017-06-29
ZA201703344B (en) 2018-08-29
MX2021001188A (es) 2021-04-19
CR20170160A (es) 2017-06-15
AR104342A1 (es) 2017-07-12
SMT202100082T1 (it) 2021-03-15
AU2015336480B2 (en) 2020-04-02
US20180237404A1 (en) 2018-08-23
US20210340114A1 (en) 2021-11-04
CY1123842T1 (el) 2022-05-27
KR102490156B1 (ko) 2023-01-18
TWI703131B (zh) 2020-09-01
PE20170669A1 (es) 2017-06-06
LT3210973T (lt) 2021-03-25
TW202042805A (zh) 2020-12-01
MA39688B1 (fr) 2021-02-26
JP2020007347A (ja) 2020-01-16
AU2015336480A2 (en) 2017-06-01
DOP2017000098A (es) 2017-07-15
CA2965465A1 (en) 2016-04-28
KR20170067791A (ko) 2017-06-16
IL285105A (en) 2021-08-31
RS61504B1 (sr) 2021-03-31
TW201714876A (zh) 2017-05-01
SI3210973T1 (sl) 2021-04-30
US20190119225A1 (en) 2019-04-25
MA39688A (fr) 2017-08-30
CO2017003699A2 (es) 2017-07-28
PH12017500747B1 (en) 2017-10-30
JP6588027B2 (ja) 2019-10-09
EA033446B1 (ru) 2019-10-31
UA121871C2 (uk) 2020-08-10
MY183209A (en) 2021-02-18
US10214498B2 (en) 2019-02-26
PT3210973T (pt) 2021-02-12
EP3210973A1 (en) 2017-08-30
CN107108506B (zh) 2022-06-21
MX2017004629A (es) 2017-06-30
DK3210973T3 (da) 2021-02-08
EA201790912A1 (ru) 2017-09-29
EP3210973B1 (en) 2020-12-02
PH12017500747A1 (en) 2017-10-30
BR112017007138A2 (pt) 2017-12-26
TWI749661B (zh) 2021-12-11
AU2015336480A1 (en) 2017-05-25
CN107108506A (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
ECSP17026687A (es) Compuesto heterocíclico
GT201700146A (es) Compuestos de triazolopirimidina y usos de los mismos
DOP2016000206A (es) Compuesto heterocíclico fusionado
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
CR20160368A (es) Compuesto heterocíclico
UY35821A (es) Compuesto heterocíclico
EA201692123A1 (ru) Стабилизированная твердыми веществами эмульсия
MX2017002670A (es) Inhibidores de glucosidasa.
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
DOP2015000140A (es) Compuesto heterocíclico
UY36315A (es) COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.
MX2016016870A (es) Compuestos heterociclicos y su uso como inhibidores de receptor huerfano relacionado con retinoide (ror) gamma-t.
CL2017000391A1 (es) Nitrógeno tricíclico que contiene compuestos para el tratamiento de una infección por neisseria gonorrhoea
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
MX2018009459A (es) Derivado de sulfonamida y composicion farmaceutica que contiene el mismo.
UY35774A (es) Compuesto heterocíclico
AR128158A2 (es) Compuesto heterocíclico
CU20160003A7 (es) Pirazololpiridinaminas sustituidas
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
CL2016002677A1 (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1.
EA201790973A1 (ru) A-антагонист в низкой дозировке для лечения adhd и болезни паркинсона
UY35650A (es) Compuesto heterocíclico
PE20160438A1 (es) Elemento de filtro, metodo para la fabricacion y uso del mismo
EA201691036A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии